Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Allison Transmission Holdings Inc Q1 2026 Earnings Call - Synergies Take Shape Amid Geopolitical Fog
Allison Transmission reported a solid Q1 2026, with adjusted diluted EPS rising 6% year-over-year to $2.57 and adjusted EBITDA climbing 22% to $362 million. The results were bolstered by a 64% surge i...
- Adjusted diluted EPS rose 6% year-over-year to $2.57, while adjusted EBITDA surged 22% to $362 million, driven by disciplined execution and the addition of the off-highway business.
- Defense revenue exploded 64% year-over-year, fueled by international track programs and new product adoption, providing a strong counterbalance to softer commercial markets.
- Legacy on-highway net sales declined 4% to $733 million, as tariff uncertainty and emissions regulation delays continue to suppress end-user purchasing decisions in North America.
- +7 more takeaways
Palantir Technologies Q1 2026 Earnings Call - U.S. Revenue Doubles as AI Platform Dominance Accelerates Growth
Palantir reported a blistering Q1 2026, with total revenue surging 85% year-over-year to $1.633 billion and U.S. revenue more than doubling at 104% growth. The company’s AI platform, AIP, is rapidly r...
- Total revenue grew 85% YoY to $1.633 billion, marking the highest reported YoY growth rate in the company’s public history.
- U.S. revenue surged 104% YoY and 19% sequentially, surpassing 100% growth for the first time since Palantir’s direct public offering.
- Rule of 40 score climbed to 145, up from 127 in Q4, reflecting simultaneous expansion in growth and profitability.
- +7 more takeaways
Nuvation Bio Q1 2026 Earnings Call - Ibtrozi Launch Shifts to First-Line Use, Driving Revenue Stacking
Nuvation Bio’s Q1 2026 results confirm a pivotal shift in the Ibtrozi launch. New patient starts held steady at roughly 200 per quarter, but for the first time, more than half of those starts were TKI...
- Nuvation Bio generated $83.2 million in total revenue for Q1 2026, driven by $18.5 million in Ibtrozi net U.S. product revenue, representing an 18% quarter-over-quarter increase.
- New patient starts remained consistent at approximately 200 per quarter for three consecutive quarters, but the patient mix shifted significantly toward first-line use.
- For the first time, over 50% of new Ibtrozi patients started therapy in the first-line setting, up from roughly 30% in the launch quarter, signaling a successful commercial transition.
- +7 more takeaways
EverQuote Q1 2026 Earnings Call - Record EBITDA Driven by AI Productivity and Carrier Growth
EverQuote delivered a strong Q1 2026, beating guidance with $190.9 million in revenue and $29.3 million in Adjusted EBITDA, up 30% year-over-year. The growth was fueled by a broad-based recovery in ca...
- Revenue grew 15% year-over-year to $190.9 million, exceeding the high end of guidance, driven by a 13% increase in auto insurance revenue and a 33% surge in home insurance revenue to $18.5 million.
- Adjusted EBITDA reached a record $29.3 million, up 30% year-over-year, representing a 15.4% margin and marking the third consecutive quarter of annualized Adjusted EBITDA at or above $100 million.
- Variable Marketing Dollars (VMD) hit a record $55.9 million, up 19% year-over-year, while Variable Marketing Margin (VMM) improved to 29.3%, reflecting better profitability from newly invested traffic channels.
- +7 more takeaways
BioMarin Pharmaceutical Inc.
BioMarin closed its acquisition of Amicus Therapeutics, marking a strategic expansion into Fabry and Pompe diseases with the addition of Galafold and Pombiliti/Opfolda. The deal accelerates the compan...
- BioMarin officially closed its acquisition of Amicus Therapeutics, adding Galafold for Fabry disease and Pombiliti/Opfolda for Pompe disease to its portfolio.
- The acquisition accelerates BioMarin's 2026 revenue growth guidance to a midpoint of 20% year-over-year, with total revenue guidance raised to $3.825 billion - $3.925 billion.
- Enzyme therapies revenue guidance for 2026 is increased to $2.725 billion - $2.775 billion, reflecting approximately 30% growth at the midpoint, driven by Amicus assets.
- +7 more takeaways
Black Hills Corporation Q1 2026 Earnings Call - Data Center Demand Drives Strategic Upside Amidst Warm Weather Headwinds
Black Hills Corporation delivered a solid start to 2026, reaffirming its $4.25-$4.45 adjusted EPS guidance despite facing one of its warmest winters on record, which suppressed demand by $0.18 per sha...
- Black Hills reaffirmed its full-year adjusted EPS guidance range of $4.25-$4.45, signaling 6% growth at the midpoint over 2025, despite weather headwinds.
- Q1 2026 GAAP EPS came in at $1.73, or $1.79 adjusted, with warm weather reducing demand by $0.18 per share compared to Q1 2025.
- The company reported $0.24 per share in new rate and rider recovery margins, which helped offset higher financing costs and lower retail usage.
- +12 more takeaways
Horace Mann Educators Q1 2026 Earnings Call - Record Core EPS Driven by P&C Margin Expansion and Group Benefits Momentum
Horace Mann Educators delivered a record first quarter for 2026, with core earnings per share of $1.28, a 20% year-over-year increase that underscores the resilience of its multi-line model. The Prope...
- Record Q1 2026 core EPS of $1.28, up 20% year-over-year, beating the prior year's record.
- Property and Casualty combined ratio improved by 5.4 points to 83.3, driven by lower catastrophe costs and disciplined underwriting.
- Group benefits sales more than tripled year-over-year to $11 million, supported by a new paid family leave product and expanded sales force.
- +7 more takeaways
Watts Water Technologies Q1 2026 Earnings Call - Record Sales Driven by Data Center Boom and Pricing Power
Watts Water Technologies delivered a record-start to 2026 with first-quarter sales of $677 million, driven by a 12% organic increase fueled by aggressive pricing and surging demand in data center cool...
- Record Q1 2026 sales of $677 million, reflecting a 21% reported and 12% organic increase driven by favorable pricing and volume.
- Data center cooling sales more than doubled quarter-over-quarter, tapping into a $1 billion addressable market and offsetting softer residential demand.
- Adjusted operating margin expanded 110 basis points to 20.1%, as price realization and productivity gains outpaced tariff costs, inflation, and acquisition dilution.
- +7 more takeaways
F&G Financial Group Q1 2026 Earnings Call - Record AUM and Fee-Based Shift Drive ROE Expansion
F&G Financial Group delivered a solid first quarter with record gross AUM of nearly $75 billion, up 11% year-over-year, driven by strong core sales in retail indexed annuities and pension risk transfe...
- Record gross AUM reached nearly $75 billion in Q1 2026, up 11% year-over-year, driven by strong core sales and disciplined opportunistic positioning.
- Fee-based strategies now account for 15% of adjusted net earnings and are targeted to grow to 25% by year-end 2028, signaling a structural shift toward higher-margin, less capital-intensive revenue.
- Management initiated a formal process to explore strategic alternatives for Peak Altitude, its owned distribution platform, to unlock value and potentially deconsolidate the business.
- +7 more takeaways
Estée Lauder Companies Q3 2026 Earnings Call - Raised FY26 Outlook on Margin Expansion and China Momentum
Estée Lauder delivered a resilient Q3 2026 with 2% organic sales growth, driven by double-digit fragrance gains and strong retail momentum in China and emerging markets. The company raised its full-ye...
- Raised full-year fiscal 2026 organic sales growth to 3% and operating margin to 10.7%-11%, up from prior guidance.
- Q3 2026 organic sales grew 2%, with double-digit fragrance growth driving performance across regions.
- Mainland China delivered high-single-digit retail sales growth for the fourth consecutive quarter, outpacing prestige beauty.
- +12 more takeaways